Search Results - "Saito, Naoyuki G."

Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization by Nikolovska-Coleska, Zaneta, Wang, Renxiao, Fang, Xueliang, Pan, Hongguang, Tomita, York, Li, Peng, Roller, Peter P., Krajewski, Krzysztof, Saito, Naoyuki G., Stuckey, Jeanne A., Wang, Shaomeng

“…The X-linked inhibitor of apoptosis protein (XIAP) is a potent cellular inhibitor of apoptosis. Designing small-molecule inhibitors that target the BIR3 domain…”
Get full text

RTOG Sarcoma Radiation Oncologists Reach Consensus on Gross Tumor Volume and Clinical Target Volume on Computed Tomographic Images for Preoperative Radiotherapy of Primary Soft Tissue Sarcoma of Extremity in Radiation Therapy Oncology Group Studies by Wang, Dian, M.D., Ph.D, Bosch, Walter, Ph.D, Roberge, David, M.D, Finkelstein, Steven E., M.D, Petersen, Ivy, M.D, Haddock, Michael, M.D, Chen, Yen-Lin E., M.D, Saito, Naoyuki G., M.D., Ph.D, Kirsch, David G., M.D., Ph.D, Hitchcock, Ying J., M.D, Wolfson, Aaron H., M.D, DeLaney, Thomas F., M.D

“…Objective To develop a Radiation Therapy Oncology Group (RTOG) atlas delineating gross tumor volume (GTV) and clinical target volume (CTV) to be used for…”
Get full text

A Retrospective Analysis of 287 Patients Undergoing Prophylactic Radiation Therapy for the Prevention of Heterotopic Ossification by Freije, Samantha L., Kushdilian, Michael V., Burney, Heather N., Zang, Yong, Saito, Naoyuki G.

“…Heterotopic ossification (HO) is a potentially disabling disorder of ectopic bone formation secondary to orthopedic surgery or trauma. In this retrospective…”
Get full text

Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report by Cerra-Franco, Alberto, Grethlein, Sara J., Bertrand, Todd E., Wooden, William A., Saito, Naoyuki G.

Get full text

An Intracranial Hemorrhage Wrapped in an Enigma by McClelland, Shearwood, Saito, Naoyuki G.

Get full text

Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer by Chen, Lujia, Wang, Ying, Cai, Chunhui, Ding, Ying, Kim, Rim S, Lipchik, Corey, Gavin, Patrick G, Yothers, Greg, Allegra, Carmen J, Petrelli, Nicholas J, Suga, Jennifer Marie, Hopkins, Judith O, Saito, Naoyuki G, Evans, Terry, Jujjavarapu, Srinivas, Wolmark, Norman, Lucas, Peter C, Paik, Soonmyung, Sun, Min, Pogue-Geile, Katherine L, Lu, Xinghua

“…A combination of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is the standard for adjuvant therapy of resected early-stage colon cancer (CC). Oxaliplatin…”
Get full text

Structure-Based Design, Synthesis, Evaluation, and Crystallographic Studies of Conformationally Constrained Smac Mimetics as Inhibitors of the X-linked Inhibitor of Apoptosis Protein (XIAP) by Sun, Haiying, Stuckey, Jeanne A, Nikolovska-Coleska, Zaneta, Qin, Dongguang, Meagher, Jennifer L, Qiu, Su, Lu, Jianfeng, Yang, Chao-Yie, Saito, Naoyuki G, Wang, Shaomeng

“…Small molecules designed to mimic the binding of Smac protein to X-linked inhibitor of apoptosis protein (XIAP) are being pursued as a promising new class of…”
Get full text

Variation in the Gross Tumor Volume and Clinical Target Volume for Preoperative Radiotherapy of Primary Large High-Grade Soft Tissue Sarcoma of the Extremity Among RTOG Sarcoma Radiation Oncologists by Wang, Dian, Bosch, Walter, Kirsch, David G, Al Lozi, Rawan, El Naqa, Issam, Roberge, David, Finkelstein, Steven E, Petersen, Ivy, Haddock, Michael, Chen, Yen-Lin E, Saito, Naoyuki G, Hitchcock, Ying J, Wolfson, Aaron H, DeLaney, Thomas F

“…Purpose To evaluate variability in the definition of preoperative radiotherapy gross tumor volume (GTV) and clinical target volume (CTV) delineated by sarcoma…”
Get full text

In Reply to O'Sullivan et al by Wang, Dian, Bosch, Walter, Roberge, David, Finkelstein, Steven E, Petersen, Ivy, Haddock, Michael, Chen, Yen-Lin E, DeLaney, Thomas F, Saito, Naoyuki G, Kirsch, David G, Hitchcock, Ying J, Wolfson, Aaron H

Get full text

Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease by Dawson, Laura A, Saito, Naoyuki G, Ratanatharathorn, Voravit, Uberti, Joseph P, Adams, Paul T, Ayash, Lois J, Reynolds, Christopher M, Silver, Samuel M, Schipper, Matthew J, Lichter, Allen S, Eisbruch, Avraham

“…This Phase I study was designed to evaluate the tolerability of involved-field radiotherapy (IFRT) to areas of persistent disease in patients with high-risk…”
Get more information

Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08 by Lu, Xinghua, Chen, Lujia, Wang, Ying, Cai, Chunhui, Kim, Rim S, Lipchik, Corey, Fumagalli, Debora, Yothers, Greg, Allegra, Carmen Joseph, Petrelli, Nicholas J., Suga, Jennifer Marie, Hopkins, Judith O., Saito, Naoyuki G., Wolmark, Norman, Lucas, Peter C., Sun, Min, Pogue-Geile, Katherine L.

“…3607 Background: Through mining The Cancer Genome Atlas (TCGA) data and a large set of transcriptomes of CRC in GEO, we constructed 15 metagenes reflecting the…”
Get full text

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev by Pogue-Geile, Katherine L., Joy, Marion E, Wang, Ying, Kim, Rim S, Gavin, Patrick G, Fumagalli, Debora, Yothers, Greg, Allegra, Carmen Joseph, Srinivasan, Ashok, Finnigan, Melanie, Jacobs, Samuel A., George, Thomas J., Suga, Jennifer Marie, Hopkins, Judith O., Saito, Naoyuki G., Wolmark, Norman, Paik, Soonmyung, Lucas, Peter C.

“…Abstract only 140 Background: NRG Oncology/NSABP C-08 tested the efficacy of adding bev to mFOLFOX in patients (pts) with stage II or III colon cancer. In an…”
Get full text

Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08 by Pogue-Geile, Katherine L., Joy, Marion, Wang, Ying, Song, Nan, Kim, Rim S., Yothers, Greg, Allegra, Carmen Joseph, Srinivasan, Ashok, Finnigan, Melanie, Jacobs, Samuel A., Paik, Soonmyung, Suga, Jennifer Marie Marie, Hopkins, Judith O., DiBella, Nicholas J., Saito, Naoyuki G., Lucas, Peter C., Wolmark, Norman

“…Abstract only 3516 Background: The purpose of this study was to quantify different molecules of TIME including T cells, macrophages, and immune checkpoint…”
Get full text

Recognition of an MHC Class I-Restricted Antigenic Peptide Can Be Modulated by para-Substitution of Its Buried Tyrosine Residues in a TCR-Specific Manner by Saito, Naoyuki G, Chang, Hsiu-Ching, Paterson, Yvonne

“…Conformational dependence of TCR contact residues of the H-2Kb molecule on the two buried tyrosine side chains of the vesicular stomatitis virus (VSV)-8…”
Get full text

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials by Esteva, Andre, Feng, Jean, van der Wal, Douwe, Huang, Shih-Cheng, Simko, Jeffry P., DeVries, Sandy, Chen, Emmalyn, Schaeffer, Edward M., Morgan, Todd M., Sun, Yilun, Ghorbani, Amirata, Naik, Nikhil, Nathawani, Dhruv, Socher, Richard, Michalski, Jeff M., Roach, Mack, Pisansky, Thomas M., Monson, Jedidiah M., Naz, Farah, Wallace, James, Ferguson, Michelle J., Bahary, Jean-Paul, Zou, James, Lungren, Matthew, Yeung, Serena, Ross, Ashley E., Sandler, Howard M., Tran, Phuoc T., Spratt, Daniel E., Pugh, Stephanie, Feng, Felix Y., Mohamad, Osama

“…Prostate cancer is the most frequent cancer in men and a leading cause of cancer death. Determining a patient’s optimal therapy is a challenge, where…”
Get full text

Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials by Esteva, Andre, Feng, Jean, van der Wal, Douwe, Huang, Shih-Cheng, Simko, Jeffry P., DeVries, Sandy, Chen, Emmalyn, Schaeffer, Edward M., Morgan, Todd M., Sun, Yilun, Ghorbani, Amirata, Naik, Nikhil, Nathawani, Dhruv, Socher, Richard, Michalski, Jeff M., Roach, Mack, Pisansky, Thomas M., Monson, Jedidiah M., Naz, Farah, Wallace, James, Ferguson, Michelle J., Bahary, Jean-Paul, Zou, James, Lungren, Matthew, Yeung, Serena, Ross, Ashley E., Sandler, Howard M., Tran, Phuoc T., Spratt, Daniel E., Pugh, Stephanie, Feng, Felix Y., Mohamad, Osama

Get full text

RTOG Sarcoma Radiation Oncologists Reach Consensus on Gross Tumor Volume (GTV) and Clinical Target Volume (CTV) on Computed Tomographic Images for Preoperative Radiotherapy of Primary Soft Tissue Sarcoma of Extremity in RTOG Studies by Wang, Dian, Bosch, Walter, Roberge, David, Finkelstein, Steven E., Petersen, Ivy, Haddock, Michael, Chen, Yen-Lin E., Saito, Naoyuki G., Kirsch, David G., Hitchcock, Ying J., Wolfson, Aaron H., DeLaney, Thomas F.

Get full text

Abstract LB-166: Characterization of a novel class of carbazole based radiation sensitizers by Saito, Naoyuki G., Commane, Mairead, Greene, Kellee F., Novototskaya, Liliya R., Purmal, Andrei A., Wang, Zhou, Gurova, Katerina V., Gudkov, Andrei V.

“…Abstract Technological advances in radiation therapy have greatly improved our ability to deliver a precise dose of radiation to a defined volumetric target…”
Get full text

Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemo-radiation: a case report by Cerra-Franco, Alberto, MD, Grethlein, Sara J., MD, Bertrand, Todd E., MD, MBA, Wooden, William A., MD, Saito, Naoyuki G., MD, PhD

“…Abstract There is a lack of published reports regarding how well patients with ichthyosis, a disorder of keratinization, tolerate a course of radiation…”
Get full text

Contribution of peptide backbone atoms to binding of an antigenic peptide to class I major histocompatibility complex molecule by Saito, Naoyuki G., Paterson, Yvonne

“…Antigenic peptides are thought to bind to class I major histocompatibility complex (MHC) molecules through three modes of interaction: van der Waals…”
Get full text